Treatment

Strategic Target Adjustment Revamps Antibiotic Development

12/21/2016

TXA-709 is a new type of antibiotic being developed by TAXIS Pharmaceuticals. The antibiotic specifically targets variants of the MRSA bacteria. TXA-709, a FtsZ-targeting benzamide prodrug, should be able to circumvent the problem of antibiotic resistance in certain bacterial infections by targeting previously neglected portions of these harmful microbes.

Rather than formulating a slightly different version of a previously effective antibiotic, TAXIS scientists are synthesizing new chemical entities with uniques mechanisms of action. This approach offers a distinct advantage when designing treatments to overcome multi-drug resistant bacteria. TXA-709 has yielded very promising results in pre-clinical trials. If approved, the drug will have the added benefit of being orally efficacious, which will make it easy to administer to patients.

For more videos, visit our partners at The Doctor's Channel.

Related Content

Pulmonology
Thomas Bauer II
Pulmonology
Thomas Bauer II, MD, on A Multidisciplinary Approach to Managing Lung Cancer
05/31/2019
Thomas Bauer II, MD, from Hackensack Meridian Health, speaks about his session at LUNGFORCE 2019. In his session, he spoke about who is included in his multidisciplinary team as well as the importance of...
05/31/2019
Lipid & Metabolic
Michael J. Bloch, MD
Lipid & Metabolic
CRS 2015: Therapeutic Advances in Hypercholesterolemia: Examining the Role of PCSK-9 Inhibitors in Addressing Unmet Needs
09/28/2015
Faculty Member Michael J. Bloch, MD, talks about PCSK9 with Co-Chair Edward Shahady, MD, FAAFP, ABCL.
09/28/2015
Women's Health
Women's Health
Female Urinary Incontinence Worsens With Age
09/03/2015
Leslie M. Rickey, MD, MPH, discusses rates of urinary incontinence in women and explains that contributing factors to are not limited to the bodily changes related to pregnancy but can also be...
09/03/2015
Mental Health
Mental Health
Michael Thase, MD on Considering Lithium as a Treatment for Depression
12/04/2019
Michael Thase, MD, weighs in on when lithium should be considered as a depression treatment and when it should it be avoided.
12/04/2019
Migraine
Stewart Tepper, MD
Migraine
Stewart Tepper, MD, on Erenumab as a Game-Changer for Chronic Migraine With or Without Acute Medication Overuse
06/18/2017
In this video, Stewart Tepper, MD, discusses the findings from his recent trial on the long-term efficacy of erenumab among patients with chronic migraine with or without acute medication overuse, and how...
06/18/2017